As a prevailing condition amongst patients, stakeholders in the hyperhidrosis treatment market are working in collaboration with researchers, scientists, and pharmaceutical frontrunners to develop less-invasive hyperhidrosis treatments. Ongoing research activities and experiments in the hyperhidrosis treatment market are based on insightful clinical trials and constructive feedback from subject patients. However, there is scope for further investigations to understand the effectiveness of less-invasive remedies for hyperhidrosis treatment.
Patients suffering from hyperhidrosis demand the need for at-home solutions that provide reasonable and helpful-relief, especially for kids. However, successful research experiments are giving rise to effective and well-endured hyperhidrosis treatment solutions for children. For instance, in September 2018, Dermira Inc. a leading medical dermatology drug innovation company, announced the launch of QBREXZA, an anticolinergenic cloth that serves as an alternative for the topical treatment of axillary hyperhidrosis. After various discussions and working in synergy with dermatologists, Dermira Inc. has been successful in understanding the lack of novel hyperhidrosis treatment alternatives, which led to the innovation of QBREXZA.
Although stakeholders are involved in extensive research & development efforts for the treatment of hyperhidrosis, the exact reason for the hyperhidrosis health condition is still vague in medical terms. However, patient satisfaction and result-oriented outcomes have always been the key focus areas of hyperhidrosis treatment providers. Also, stakeholders are taking efforts to continuously improve the efficacy of non-surgical treatments for hyperhidrosis through clinically-proven data and statistics.
The hyperhidrosis treatment market is currently valued at ~US$ 1.2 billion, and is estimated to grow at a moderate speed for the next decade. Recent studies show that, one of the major reasons for the sluggish growth of the hyperhidrosis treatment market is due to a common orthodox belief that hyperhidrosis is not a medical condition, and that the various types of hyperhidrosis cannot be medically treated.
Current findings propose that, both, the severity and prevalence are in excess than previously thought, which is likely create an upsurge in the demand for effective hyperhidrosis treatment in the coming years. Market players will experience relentless pressures to create awareness about the disease and availability of effective hyperhidrosis treatments among patients.
While the potential rise in awareness will boost the growth of the hyperhidrosis market in the coming years, the side effects of these treatments will give rise to the need for technologically-advanced and safer treatments. For example, topical treatments such as aluminum chloride antiperspirants are effective on a short-term basis, but may lead to side effects such as intolerable skin irritation. Hence, modern hyperhidrosis treatment alternatives are triggering the need for newer options such as laser therapy, topical botulinum toxin type A, and micro-focused ultrasound treatment.
The increasing prevalence of axillary hyperhidrosis has been triggering the demand for effective treatments, such as fractional microneedle radiofrequency (FMR) treatment, tap water iontophoresis, and microwave technology. In 2018, axillary hyperhidrosis treatments accounted for more than half the revenue share of the global market, and this is likely to increase in the coming years. Emerging trends in the hyperhidrosis treatment market include the increasing availability of treatments for axillary hyperhidrosis in hospitals and ambulatory surgical centers, as well as botox injections in dermatology clinics and cosmetic centers, which is likely to shape the future of this landscape.
Healthcare providers are studying hyperhidrosis treatments that involve radiofrequency microneedling and their outcomes seen in hyperhidrosis patients. Stakeholders are trying to find answers whether the fractional microneedle radiofrequency treatment has long-term benefits, especially for patients suffering from primary axillary hyperhidrosis. These studies were evaluated using the hyperhidrosis disease severity scale (HDSS), which demonstrated drastic improvements in patients after treatment.
Further results that enfolded suggested that, FMR is one of the most secure and effective means for non-invasive therapy. However, it is emphasized that the FMR treatment be repeated after one year to avoid a relapse of the hyperhidrosis disease, particularly for patients who are overweight with high BMIs (Body Mass Index).
Another hyperhidrosis treatment that is gaining awareness in patients is tap water iontophoresis, in which, an ionized substance is passed through the skin by the means of direct electric current. After various clinical trials, healthcare providers have observed significant improvements in patients suffering from plantar and palmar hyperhidrosis. These positive results helped in improving the quality of life of patients and a significant reduction in the sweat secretion rate.
In February 2018, Sientra, a leading medical aesthetics company, announced the launch of the new miraDry fresh™ protocol for the miraDry® system, which can permanently reduce underarm odor, sweat, and hair of all colors with quicker and effective results. The FDA-approved miraDry has also received a CE-mark in Europe, and is available in several ambulatory surgical centers and cosmetic centers. It uses the cutting-edge non-surgical microwave technology for the treatment of axillary hyperhidrosis, and owing to the effectiveness of non-surgical microwave energy destruction of sweat glands, the microwave technology is likely to gain immense popularity among stakeholders in the coming years.
Another type of hyperhidrosis treatment that is expected to gain in popularity is Botulinum toxin A. Based on various studies, research, and clinical trials amongst patients, Botulinum toxin A (BoNTA) has been accepted by many healthcare providers as a safe, effective, and long-lasting hyperhidrosis treatment for axillae, face, palms, and soles.
Though Botulinum toxin A accounts for nearly one-fourth revenue share of the market, these injections are not recommended to patients who have previously undergone the surgical debulking of sweat glands or have severe blood-clotting disorders. Thereby, the adoption of this treatment in the hyperhidrosis treatment market is expected to decline slowly in the coming years
One of the major disadvantages for hyperhidrosis treatment, especially catering to Botulinum toxin injections, is its transient efficacy in patients who become less tolerant to the dosage as and when they become accustomed to the treatment. Another challenge that is adversely affecting the hyperhidrosis treatment market is the financial burden and psychological distress that patients experience as many medical insurance companies do not have the provision for hyperhidrosis treatment.
Due to this phenomenon, patients are reluctant to pay out-of-pocket for newer treatments that are introduced in the hyperhidrosis treatment landscape, even though they are more effective than the traditional options. Thus, the onus is on policy makers to empathize on patient awareness and overall impact of hyperhidrosis treatments on their quality of life.
In spite of market redundancies, stakeholders such as pharmaceutical companies, medical aesthetics companies, and other healthcare providers are focusing on increasing the penetration of hyperhidrosis treatments by introducing high-accuracy, non-surgical, and topical treatments. Also, research studies over the last decade reveal that, pharmacological treatments have shown effective outcomes with reduced patient-reported cases for severe reoccurrence of hyperhidrosis. For instance, GlaxoSmithKline, a leading British multinational pharmaceutical company, conducted a research experiment to study the effects of Umeclidinium, a type of anticholinergenic drug, on the palms of patients suffering from palmar hyperhidrosis, and its role as a topical treatment option. Overall, it was found that, the drug had positive results on the patients.
Analysts’ View
Analysts of the hyperhidrosis treatment market have a promising outlook for the forecast period of 2019-2027. North America is anticipated to remain as the target market for healthcare providers. However, the hyperhidrosis treatment market is estimated to grow in Asia Pacific also, due to the steadily increasing prevalence of hyperhidrosis in the region. Stakeholders can increase the penetration of non-surgical and topical treatments to suit the changing requirements and perception among hyperhidrosis patients. Novel treatments such as radiofrequency microneedling, and iontophoresis are gaining attention from healthcare organizations as well as patients.
However, stakeholders need to tackle the common misconceptions of patients about the disease that are triggered due to the lack of knowledge on the treatment options available, besides the lack of provisions from medical policy makers and deprived monetary funding options for patients. Healthcare providers can overcome these restraints by creating awareness about patient satisfaction amongst medical policy makers, which will help patients to pay-from-pocket for newer and more effective hyperhidrosis treatment therapies, significantly improving their quality of life and reducing psychological distress.
Idiopathic Hyperhidrosis
Rise in Demand for Minimally-invasive and Non-invasive Therapeutic Procedures to Boost Market
Asia Pacific Hyperhidrosis Treatment Market to Grow at a Rapid Pace
Global Hyperhidrosis Treatment Market: Segment Analysis
Global Hyperhidrosis Treatment Market: Regional Outlook
Companies Mentioned in Report
The report also profiles major players in the global hyperhidrosis treatment market based on various attributes such as company overview, financial overview, treatment types, business strategies, and recent developments. These include
Hyperhidrosis Treatment Market – Segmentation
In order to understand the finer and broader nuances of the market, the segmentation of the hyperhidrosis treatment market has been done on the basis of treatment type, hyperhidrosis type, end user, and region. This is one way by which incremental opportunities can be assessed in the market landscape.
|
Treatment Type |
Botulinum Toxin A Iontophoresis Surgical Treatments Topical Treatments Non-surgical Microwave Energy Destruction of Sweat Glands Others |
|
Hyperhidrosis Type |
Axillary Hyperhidrosis Palmar Hyperhidrosis Plantar Hyperhidrosis Others |
|
End User |
Hospitals Ambulatory Surgical Centers Others (Dermatology Clinics and Cosmetic Centers) |
|
Region |
North America Europe Asia Pacific Latin America Middle East & Africa |
Hyperhidrosis treatment market to reach a value of ~US$ 1.6 Bn by 2027
Hyperhidrosis treatment market is projected to grow at a CAGR of ~4% between the years 2019 to 2027
Hyperhidrosis treatment market is driven by rise in demand for minimally-invasive and non-invasive therapeutic procedures
The botulinum toxin A segment is projected to dominate the global hyperhidrosis treatment market during the forecast period
Key players in the hyperhidrosis treatment market include GlaxoSmithKline plc, Ulthera, Inc., TheraVida, Dermira, Inc., Revance Therapeutics, Inc., Allergan plc, Miramar Labs, Inc.
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Global Hyperhidrosis Treatment Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027
3.2. Global Hyperhidrosis Treatment Market: Market Snapshot
4. Market Overview
4.1. Global Hyperhidrosis Treatment Market: Treatment Overview
4.2. Global Hyperhidrosis Treatment Market: Key Industry Developments
4.3. Market Dynamics
4.4. Drivers and Restraints Snapshot Analysis
4.5. Drivers
4.5.1. Surge in demand for minimally invasive and non-invasive therapeutic procedures
4.5.2. Rise in social embarrassment due to anxiety sweating
4.6. Restraints
4.6.1. Short time results and repetitive nature of aesthetic and therapeutic procedures
4.6.2. High cost of procedures and unavailability of reimbursement policies
4.7. Opportunities
4.8. Global Hyperhidrosis Treatment Market Revenue Projections (US$ Mn), 2017–2027
5. Key Insights
5.1. Clinical Trial Pipeline Analysis
5.2. Key Merger and Acquisitions
5.3. Average Cost of Hyperhidrosis Treatment
6. Global Hyperhidrosis Treatment Market Analysis, by Treatment Type
6.1. Introduction
6.2. Global Hyperhidrosis Treatment Market Size and Forecast, by Treatment Type
6.2.1. Botulinum Toxin A
6.2.2. Iontophoresis
6.2.3. Surgical Treatments
6.2.4. Topical Treatments
6.2.5. Non-surgical Microwave Energy Destruction of Sweat Glands
6.2.6. Others
6.3. Global Hyperhidrosis Treatment Market Analysis, by Treatment Type
6.4. Global Hyperhidrosis Treatment Market Attractiveness Analysis, by Treatment Type
7. Global Hyperhidrosis Treatment Market Analysis, by Hyperhidrosis Type
7.1. Introduction
7.2. Global Hyperhidrosis Treatment Market Size and Forecast, by Hyperhidrosis Type
7.2.1. Axillary Hyperhidrosis
7.2.2. Palmar Hyperhidrosis
7.2.3. Plantar Hyperhidrosis
7.2.4. Others (craniofacial, etc.)
7.3. Global Hyperhidrosis Treatment Market Analysis, by Hyperhidrosis Type
7.4. Global Hyperhidrosis Treatment Market Attractiveness Analysis, by Hyperhidrosis Type
8. Global Hyperhidrosis Treatment Market Analysis, by End-user
8.1. Introduction
8.2. Global Hyperhidrosis Treatment Market Size and Forecast, by End-user
8.2.1. Hospitals
8.2.2. Ambulatory Surgical Centers
8.2.3. Others (dermatology clinics & cosmetic centers)
8.3. Global Hyperhidrosis Treatment Market Analysis, by End-user
8.4. Global Hyperhidrosis Treatment Market Attractiveness Analysis, by End-user
9. Global Hyperhidrosis Treatment Market Analysis, by Region
9.1. Global Hyperhidrosis Treatment Market Size and Forecast, by Region, 2017–2027
9.1.1. North America
9.1.2. Europe
9.1.3. Asia Pacific
9.1.4. Latin America
9.1.5. Middle East & Africa
9.2. Global Hyperhidrosis Treatment Market Analysis, by Region
9.3. Global Hyperhidrosis Treatment Market Attractiveness Analysis, by Region
10. North America Hyperhidrosis Treatment Market Analysis
10.1. North America Hyperhidrosis Treatment Market
10.2. North America Hyperhidrosis Treatment Market Overview
10.3. North America Hyperhidrosis Treatment Market Size and Forecast, by Treatment Type
10.3.1. Botulinum Toxin A
10.3.2. Iontophoresis
10.3.3. Surgical Treatments
10.3.4. Topical Treatments
10.3.5. Non-surgical Microwave Energy Destruction of Sweat Glands
10.3.6. Others
10.4. North America Hyperhidrosis Treatment Market Size and Forecast, by Hyperhidrosis Type
10.4.1. Axillary Hyperhidrosis
10.4.2. Palmar Hyperhidrosis
10.4.3. Plantar Hyperhidrosis
10.4.4. Others (craniofacial, etc.)
10.5. North America Hyperhidrosis Treatment Market Size and Forecast, by End-user
10.5.1. Hospitals
10.5.2. Ambulatory Surgical Centers
10.5.3. Others (dermatology clinics & cosmetic centers)
10.6. North America Hyperhidrosis Treatment Market Forecast, by Country
10.6.1. U.S.
10.6.2. Canada
10.7. North America Hyperhidrosis Treatment Market Attractiveness Analysis
10.7.1. By Treatment Type
10.7.2. By Hyperhidrosis Type
10.7.3. By End-user
10.7.4. By Country
11. Europe Hyperhidrosis Treatment Market Analysis
11.1. Europe Hyperhidrosis Treatment Market
11.2. Europe Hyperhidrosis Treatment Market Overview
11.3. North America Hyperhidrosis Treatment Market Size and Forecast, by Treatment Type
11.3.1. Botulinum Toxin A
11.3.2. Iontophoresis
11.3.3. Surgical Treatments
11.3.4. Topical Treatments
11.3.5. Non-surgical Microwave Energy Destruction of Sweat Glands
11.3.6. Others
11.4. North America Hyperhidrosis Treatment Market Size and Forecast, by Hyperhidrosis Type
11.4.1. Axillary Hyperhidrosis
11.4.2. Palmar Hyperhidrosis
11.4.3. Plantar Hyperhidrosis
11.4.4. Others (craniofacial, etc.)
11.5. North America Hyperhidrosis Treatment Market Size and Forecast, by End-user
11.5.1. Hospitals
11.5.2. Ambulatory Surgical Centers
11.5.3. Others (dermatology clinics & cosmetic centers)
11.6. Europe Hyperhidrosis Treatment Market Forecast, by Country/Sub-region
11.6.1. U.K.
11.6.2. France
11.6.3. Germany
11.6.4. Spain
11.6.5. Italy
11.6.6. Rest of Europe
11.7. Europe Hyperhidrosis Treatment Market Attractiveness Analysis
11.7.1. By Treatment Type
11.7.2. By Hyperhidrosis Type
11.7.3. By End-user
11.7.4. By Country/Sub-region
12. Asia Pacific Hyperhidrosis Treatment Market Analysis
12.1. Asia Pacific Hyperhidrosis Treatment Market Key Findings
12.2. Asia Pacific Hyperhidrosis Treatment Market Overview
12.3. North America Hyperhidrosis Treatment Market Size and Forecast, by Treatment Type
12.3.1. Botulinum Toxin A
12.3.2. Iontophoresis
12.3.3. Surgical Treatments
12.3.4. Topical Treatments
12.3.5. Non-surgical Microwave Energy Destruction of Sweat Glands
12.3.6. Others
12.4. North America Hyperhidrosis Treatment Market Size and Forecast, by Hyperhidrosis Type
12.4.1. Axillary Hyperhidrosis
12.4.2. Palmar Hyperhidrosis
12.4.3. Plantar Hyperhidrosis
12.4.4. Others (craniofacial, etc.)
12.5. North America Hyperhidrosis Treatment Market Size and Forecast, by End-user
12.5.1. Hospitals
12.5.2. Ambulatory Surgical Centers
12.5.3. Others (dermatology clinics & cosmetic centers)
12.6. Asia Pacific Hyperhidrosis Treatment Market Forecast, by Country/Sub-region
12.6.1. China
12.6.2. India
12.6.3. Japan
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Asia Pacific Hyperhidrosis Treatment Market Attractiveness Analysis
12.7.1. By Treatment Type
12.7.2. By Hyperhidrosis Type
12.7.3. By End-user
12.7.4. By Country/Sub-region
13. Latin America Hyperhidrosis Treatment Market Analysis
13.1. Latin America Hyperhidrosis Treatment Market Key Findings
13.2. Latin America Hyperhidrosis Treatment Market Overview
13.3. North America Hyperhidrosis Treatment Market Size and Forecast, by Treatment Type
13.3.1. Botulinum Toxin A
13.3.2. Iontophoresis
13.3.3. Surgical Treatments
13.3.4. Topical Treatments
13.3.5. Non-surgical Microwave Energy Destruction of Sweat Glands
13.3.6. Others
13.4. North America Hyperhidrosis Treatment Market Size and Forecast, by Hyperhidrosis Type
13.4.1. Axillary Hyperhidrosis
13.4.2. Palmar Hyperhidrosis
13.4.3. Plantar Hyperhidrosis
13.4.4. Others (craniofacial, etc.)
13.5. North America Hyperhidrosis Treatment Market Size and Forecast, by End-user
13.5.1. Hospitals
13.5.2. Ambulatory Surgical Centers
13.5.3. Others (dermatology clinics & cosmetic centers)
13.6. Latin America Hyperhidrosis Treatment Market Forecast, by Country/Sub-region
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Latin America Hyperhidrosis Treatment Market Attractiveness Analysis
13.7.1. By Treatment Type
13.7.2. By Hyperhidrosis Type
13.7.3. By End-user
13.7.4. By Country/Sub-region
14. Middle East & Africa Hyperhidrosis Treatment Market Analysis
14.1. Middle East & Africa Hyperhidrosis Treatment Market
14.2. Hyperhidrosis Treatment Market Overview
14.3. North America Hyperhidrosis Treatment Market Size and Forecast, by Treatment Type
14.3.1. Botulinum Toxin A
14.3.2. Iontophoresis
14.3.3. Surgical Treatments
14.3.4. Topical Treatments
14.3.5. Non-surgical Microwave Energy Destruction of Sweat Glands
14.3.6. Others
14.4. North America Hyperhidrosis Treatment Market Size and Forecast, by Hyperhidrosis Type
14.4.1. Axillary Hyperhidrosis
14.4.2. Palmar Hyperhidrosis
14.4.3. Plantar Hyperhidrosis
14.4.4. Others (craniofacial, etc.)
14.5. North America Hyperhidrosis Treatment Market Size and Forecast, by End-user
14.5.1. Hospitals
14.5.2. Ambulatory Surgical Centers
14.5.3. Others (dermatology clinics & cosmetic centers)
14.6. Middle East & Africa Hyperhidrosis Treatment Market Forecast, by Country/Sub-region
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Middle East & Africa Hyperhidrosis Treatment Market Attractiveness Analysis
14.7.1. By Treatment Type
14.7.2. By Hyperhidrosis Type
14.7.3. By End-user
14.7.4. By Country/Sub-region
15. Competitive Landscape
15.1. Company Profiles
15.1.1. GlaxoSmithKline plc.
15.1.1.1. Overview (HQ, Employee Strength, Business Segments)
15.1.1.2. Financials
15.1.1.3. Recent Developments
15.1.1.4. Strategy
15.1.2. Allergan plc
15.1.2.1. Overview (HQ, Employee Strength, Business Segments)
15.1.2.2. Financials
15.1.2.3. Recent Developments
15.1.2.4. Strategy
15.1.3. Ulthera, Inc.
15.1.3.1. Overview (HQ, Employee Strength, Business Segments)
15.1.3.2. Financials
15.1.3.3. Recent Developments
15.1.3.4. Strategy
15.1.4. TheraVida
15.1.4.1. Overview (HQ, Employee Strength, Business Segments)
15.1.4.2. Financials
15.1.4.3. Recent Developments
15.1.4.4. Strategy
15.1.5. Dermira, Inc.
15.1.5.1. Overview (HQ, Employee Strength, Business Segments)
15.1.5.2. Financials
15.1.5.3. Recent Developments
15.1.5.4. Strategy
15.1.6. Revance Therapeutics, Inc.
15.1.6.1. Overview (HQ, Employee Strength, Business Segments)
15.1.6.2. Financials
15.1.6.3. Recent Developments
15.1.6.4. Strategy
15.1.7. Miramar Labs, Inc.
15.1.7.1. Overview (HQ, Employee Strength, Business Segments)
15.1.7.2. Financials
15.1.7.3. Recent Developments
15.1.7.4. Strategy
List of Tables
TABLE 1 Global Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2027
TABLE 2 Global Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Hyperhidrosis Type, 2017–2027
TABLE 3 Global Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2027
TABLE 4 Global Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Region, 2017–2027
TABLE 5 North America Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2027
TABLE 6 North America Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2027
TABLE 7 North America Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Hyperhidrosis Type, 2017–2027
TABLE 8 North America Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2027
TABLE 9 Europe Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 10 Europe Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2027
TABLE 11 Europe Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Hyperhidrosis Type, 2017–2027
TABLE 12 Europe Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2027
TABLE 13 Asia Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 14 Asia Pacific Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2027
TABLE 15 Asia Pacific Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Hyperhidrosis Type, 2017–2027
TABLE 16 Asia Pacific Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2027
TABLE 17 Latin America Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 18 Latin America Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2027
TABLE 19 Latin America Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Hyperhidrosis Type, 2017–2027
TABLE 20 Latin America Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2027
TABLE 21 Middle East & Africa Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 22 Middle East & Africa Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2027
TABLE 23 Middle East & Africa Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by Hyperhidrosis Type, 2017–2027
TABLE 24 Middle East & Africa Hyperhidrosis Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2027
List of Figures
FIG. 1 Global Hyperhidrosis Treatment Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027
FIG. 2 Global Hyperhidrosis Treatment Market Revenue Projection (US$ Mn), 2017–2027
FIG. 3 Global Hyperhidrosis Treatment Market Value Share, by Treatment Type, 2018
FIG. 4 Global Hyperhidrosis Treatment Market Value Share, by Hyperhidrosis Type, 2018
FIG. 5 Global Hyperhidrosis Treatment Market Value Share, by Region, 2018
FIG. 6 Global Hyperhidrosis Treatment Market Value Share, by End-user, 2018
FIG. 7 Global Hyperhidrosis Treatment Market Value Share Analysis, by Treatment Type, 2018 and 2027
FIG. 8 Global Hyperhidrosis Treatment Market Revenue (US$ Mn), by Botulinum Toxin A, 2017–2027
FIG. 9 Global Hyperhidrosis Treatment Market Revenue (US$ Mn), by Iontophoresis, 2017–2027
FIG. 10 Global Hyperhidrosis Treatment Market Revenue (US$ Mn), by Surgical Treatments, 2017–2027
FIG. 11 Global Hyperhidrosis Treatment Market Revenue (US$ Mn), by Topical Treatments, 2017–2027
FIG. 12 Global Hyperhidrosis Treatment Market Revenue (US$ Mn), by Non-surgical Microwave Energy Destruction of Sweat Glands, 2017–2027
FIG. 13 Global Hyperhidrosis Treatment Market Revenue (US$ Mn), by Others, 2017–2027
FIG. 14 Global Hyperhidrosis Treatment Market Attractiveness Analysis, by Treatment Type, 2019–2027
FIG. 15 Global Hyperhidrosis Treatment Market Value Share Analysis, by Hyperhidrosis Type, 2018 and 2027
FIG. 16 Global Hyperhidrosis Treatment Market Revenue (US$ Mn), by Axillary Hyperhidrosis, 2017–2027
FIG. 17 Global Hyperhidrosis Treatment Market Revenue (US$ Mn), by Palmar Hyperhidrosis, 2017–2027
FIG. 18 Global Hyperhidrosis Treatment Market Revenue (US$ Mn), by Plantar Hyperhidrosis, 2017–2027
FIG. 19 Global Hyperhidrosis Treatment Market Revenue (US$ Mn), by Others, 2017–2027
FIG. 20 Global Hyperhidrosis Treatment Market Attractiveness Analysis, by Hyperhidrosis Type, 2019–2027
FIG. 21 Global Hyperhidrosis Treatment Market Value Share Analysis, by End-user, 2018 and 2027
FIG. 22 Global Hyperhidrosis Treatment Market Revenue (US$ Mn), by Hospitals, 2017–2027
FIG. 23 Global Hyperhidrosis Treatment Market Revenue (US$ Mn), by Ambulatory Surgical Centers, 2017–2027
FIG. 24 Global Hyperhidrosis Treatment Market Revenue (US$ Mn), by Others (dermatology clinics & cosmetic centers), 2017–2027
FIG. 25 Global Hyperhidrosis Treatment Market Attractiveness Analysis, by End-user 2019–2027
FIG. 26 Global Hyperhidrosis Treatment Market Value Share, by Region, 2018 and 2027
FIG. 27 Global Hyperhidrosis Treatment Market Attractiveness, by Region, 2019–2027
FIG. 28 North America Hyperhidrosis Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019–2027
FIG. 29 North America Hyperhidrosis Treatment Market Value Share Analysis, by Country, 2018 and 2027
FIG. 30 North America Hyperhidrosis Treatment Market Attractiveness, by Country, 2019–2027
FIG. 31 North America Hyperhidrosis Treatment Market Value Share Analysis, by Treatment Type, 2018 and 2027
FIG. 32 North America Hyperhidrosis Treatment Market Attractiveness, by Treatment Type, 2019–2027
FIG. 33 North America Hyperhidrosis Treatment Market Value Share Analysis, by Hyperhidrosis Type, 2018 and 2027
FIG. 34 North America Hyperhidrosis Treatment Market Attractiveness, by Hyperhidrosis Type, 2019–2027
FIG. 35 North America Hyperhidrosis Treatment Market Value Share Analysis, by End-user, 2018 and 2027
FIG. 36 North America Hyperhidrosis Treatment Market Attractiveness, by End-user, 2019–2027
FIG. 37 Europe Hyperhidrosis Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019–2027
FIG. 38 Europe Hyperhidrosis Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
FIG. 39 Europe Hyperhidrosis Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 40 Europe Hyperhidrosis Treatment Market Value Share Analysis, by Treatment Type, 2018 and 2027
FIG. 41 Europe Hyperhidrosis Treatment Market Attractiveness, by Treatment Type, 2019–2027
FIG. 42 Europe Hyperhidrosis Treatment Market Value Share Analysis, by Hyperhidrosis Type, 2018 and 2027
FIG. 43 Europe Hyperhidrosis Treatment Market Attractiveness, by Hyperhidrosis Type, 2019–2027
FIG. 44 Europe Hyperhidrosis Treatment Market Value Share Analysis, by End-user, 2018 and 2027
FIG. 45 Europe Hyperhidrosis Treatment Market Attractiveness, by End-user, 2019–2027
FIG. 46 Asia Pacific Hyperhidrosis Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019–2027
FIG. 47 Asia Pacific Hyperhidrosis Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
FIG. 48 Asia Pacific Hyperhidrosis Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 49 Asia Pacific Hyperhidrosis Treatment Market Value Share Analysis, by Treatment Type, 2018 and 2027
FIG. 50 Asia Pacific Hyperhidrosis Treatment Market Attractiveness, by Treatment Type, 2019–2027
FIG. 51 Asia Pacific Hyperhidrosis Treatment Market Value Share Analysis, by Hyperhidrosis Type, 2018 and 2027
FIG. 52 Asia Pacific Hyperhidrosis Treatment Market Attractiveness, by Hyperhidrosis Type, 2019–2027
FIG. 53 Asia Pacific Hyperhidrosis Treatment Market Value Share Analysis, by End-user, 2018 and 2027
FIG. 54 Asia Pacific Hyperhidrosis Treatment Market Attractiveness, by End-user, 2019–2027
FIG. 55 Latin America Hyperhidrosis Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019–2027
FIG. 56 Latin America Hyperhidrosis Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
FIG. 57 Latin America Hyperhidrosis Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 58 Latin America Hyperhidrosis Treatment Market Value Share Analysis, by Treatment Type, 2018 and 2027
FIG. 59 Latin America Hyperhidrosis Treatment Market Attractiveness, by Treatment Type, 2019–2027
FIG. 60 Latin America Hyperhidrosis Treatment Market Value Share Analysis, by Hyperhidrosis Type, 2018 and 2027
FIG. 61 Latin America Hyperhidrosis Treatment Market Attractiveness, by Hyperhidrosis Type, 2019–2027
FIG. 62 Latin America Hyperhidrosis Treatment Market Value Share Analysis, by End-user, 2018 and 2027
FIG. 63 Latin America Hyperhidrosis Treatment Market Attractiveness, by End-user, 2019–2027
FIG. 64 Middle East & Africa Hyperhidrosis Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2019–2027
FIG. 65 Middle East & Africa Hyperhidrosis Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
FIG. 66 Middle East & Africa Hyperhidrosis Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 67 Middle East & Africa Hyperhidrosis Treatment Market Value Share Analysis, by Treatment Type, 2018 and 2027
FIG. 68 Middle East & Africa Hyperhidrosis Treatment Market Attractiveness, by Treatment Type, 2019–2027
FIG. 69 Middle East & Africa Hyperhidrosis Treatment Market Value Share Analysis, by Hyperhidrosis Type, 2018 and 2027
FIG. 70 Middle East & Africa Hyperhidrosis Treatment Market Attractiveness, by Hyperhidrosis Type, 2019–2027
FIG. 71 Middle East & Africa Hyperhidrosis Treatment Market Value Share Analysis, by End-user, 2018 and 2027
FIG. 72 Middle East & Africa Hyperhidrosis Treatment Market Attractiveness, by End-user, 2019–2027
FIG. 73 GlaxoSmithKline plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018
FIG. 74 GlaxoSmithKline plc Marketing & Sales and R&D Expenses, 2016–2018
FIG. 75 GlaxoSmithKline plc Breakdown of Net Sales, by Business Segment, 2018
FIG. 76 GlaxoSmithKline plc Breakdown of Net Sales, by Region, 2018
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Hyperhidrosis Treatment Market
